Switch View
© Globe Newswire
24.09.2025
ISIN: US67092M2089
Nutriband Inc.
NTRB
LISTED
NASDAQ
Nutriband Inc. to Present at the MicroCap Rodeo Conference
News Preview
Thursday, September 25, 2025 in New York City Thursday, September 25, 2025 in New York City...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US45254E1073
Immuneering Corp
IMRX
LISTED
NASDAQ
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
News Preview
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Placement to Sanofi...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US00534A1025
Invivyd Inc
IVVD
LISTED
NASDAQ
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
News Preview
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 201...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
24.09.2025
ISIN: US45254E1073
Immuneering Corp
IMRX
LISTED
NASDAQ
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
News Preview
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
24.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Deadline Alert: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). Jasper investors have until November 18, 2025 to file a lead plaintiff m...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.09.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
News Preview
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK populationThe facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth CAM...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). Jasper investors have until November 18, 2025 to file a lead plaintiff...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Rosen Law Firm Urges Cytokinetics, Inc. (NASDAQ: CYTK) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025. Cytokinetics describes itself as a “biopharmaceutical company focused on discovering, developing, and commercializing first-in-c...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US00404A1097
Acadia Healthcare Company Inc
ACHC
LISTED
NASDAQ
Acadia Healthcare Issues Statement Highlighting Commitment to Value Creation
News Preview
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today issued the following statement:
Our Board of Directors and management team are steadfast in our commitment to enhancing long-term shareholder value. We regularly communicate with our shareholders regarding our value creation plan and welcome constructive input as we move forward.
At Acadia,...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Semler Scientific
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Semler Scientific To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Semler Scientific between March 10, 2021 and April 15, 2025 and would like to discuss your legal rig...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – LFMD
News Preview
The DJS Law Group reminds investors of a class action lawsuit against LifeMD, Inc. (“LifeMD” or “the Company”) (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of LFMD during the class p...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
24.09.2025
ISIN: US29350E1047
Enochian Biosciences, Inc
ENOB
LISTED
NASDAQ
Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split
News Preview
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price LOS ANGELES, CA / ACCESS Newswire / September 24, 2025 / Lunai Bioworks, Inc. (Nasdaq:RENB) ("Lunai Bioworks" or the "Company"), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that the Company's B...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nutex Health
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Nutex To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi &...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In CYTK To Contact Him Directly To Discuss Their Options
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Savara To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Fa...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LifeMD To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Fa...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Semler Scientific, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SMLR
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SMLR during...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LNTH To Contact Him Directly To Discuss Their Options
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruq...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0000032526
Guerbet SA
GBT
LISTED
EURONEXT
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France
News Preview
H1 2025 results...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US92337F1075
Veracyte Inc
VCYT
LISTED
NASDAQ
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men with recurrent prostate cancer will be presented at ASTRO 2025, the annual meeting of the American Society for Radiation Oncology. The findings were der...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON plc Schedules Third Quarter 2025 Earnings Conference Call
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations
News Preview
Press release – No. 14 / 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: KR7328130000
Lunit Inc.
328130
LISTED
KOE
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
News Preview
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for pharmaceutical research and development. Under the pa...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US0028241000
Abbott Laboratories
ABT
LISTED
NYSE
Abbott Hosts Conference Call for Third-Quarter Earnings
News Preview
ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.
The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor R...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US4131971040
Harmony Biosciences Holdings Inc
HRMY
LISTED
NASDAQ
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate.
Kuma...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
News Preview
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) today announced that it has filed a definitive proxy statement and GREEN proxy card with the U.S. Securities and Exchange Commission (the “SEC”)...
Themefolio
Profiler
Peergroup
© Newsfile
24.09.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Advances Commercialization Planning for Breakthrough Hearing Device as FDA Clinical Trial Remains On Track
News Preview
The Company Begins Strategic Preparations To Support Anticipated Demand And Optimization Of The Acclaim® Fully Implanted Cochlear Implant OpportunitySix-month follow-up visits are now underway and will continue over the next two monthsWhite Bear Lake, Minnesota--(Newsfile Corp. - September 24, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Centene Earns Spot on Forbes® First-Ever Ranking of Top U.S. Company Cultures America's Best Employers for Company Culture™
News Preview
Centene ranked among top 20 in U.S. insurance sector
ST. LOUIS, Sept. 24, 2025 /PRNewswire/ -- Centene Corporation ("Centene") [NYSE: CNC], a leading healthcare enterprise committed to helping people live healthier lives, has been named to the inaugural 2025 Forbes® America's Best Employers for Company Culture™ list. Ranking among the top third...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US92854B1098
Vivani Medical, Inc.
VANI
LISTED
NASDAQ
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
News Preview
ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US88322Q1085
TG Therapeutics Inc
TGTX
LISTED
NASDAQ
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
News Preview
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US5019761049
Kyverna Therapeutics, Inc.
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
News Preview
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: CA74040N1069
Predictmedix AI Inc
PMED
LISTED
CSE
Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader
News Preview
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms....
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US0042251084
ACADIA Pharmaceuticals Inc
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General and Special Meeting
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED) (NASDAQ:CGC) announced today that it has extended the deadline for the submission of proxies related to its upcoming annual general and special meeting of shareholders (the “Meeting”) to September 26, 2025 at 9:00 AM ET. The Meeting will be held later the same day, at 1:00 PM...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the P...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US09073M1045
Bio-Techne Corp
TECH
LISTED
NASDAQ
Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report
News Preview
Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions
MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the compa...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
ISIN: US6707031075
Nuvalent Inc
NUVL
LISTED
NASDAQ
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
News Preview
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participa...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US5526411021
MAIA Biotechnology Inc
MAIA
LISTED
XASE
MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
News Preview
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC)...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US01625V1044
Alignment Healthcare Inc
ALHC
LISTED
NASDAQ
Aging in Place, Limited Access to Medical Care and Economic Insecurity Threaten U.S. Senior Health
News Preview
New Alignment Health study shows nearly 2 in 5 seniors who experience loneliness say it’s impacting their health, 1 in 4 who have medical debt owe debt equal to 4+ months of living expenses New Alignment Health study shows nearly 2 in 5 seniors who experience loneliness say it’s impacting their health, 1 in 4 who have medical debt owe debt equal to...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US50127T1097
Kura Oncology Inc
KURA
LISTED
NASDAQ
Kura Oncology to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
News Preview
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the hum...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
News Preview
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
News Preview
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
News Preview
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US1717571079
Cidara Therapeutics, Inc.
CDTX
LISTED
NASDAQ
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
News Preview
- Update based on FDA End-of- Phase 2 meeting outcome...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.09.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Gerresheimer nimmt Stellung zur Prüfung durch die BaFin
News Preview
Gerresheimer nimmt Stellung zur Prüfung durch die BaFin
Düsseldorf, 24. September 2025. Die Gerresheimer AG (ISIN: DE000A0LD6E6), wurde von der Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) über die Einleitung einer anlassbezogenen Bilanzkontrollprüfung informiert.
Die Prüfung betrifft nach Angaben der BaFin die Gewinnrealisierung aus......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.09.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Gerresheimer comments on the audit by German BaFin
News Preview
Gerresheimer comments on the audit by German BaFin
Duesseldorf, 24. September 2025. Gerresheimer AG (ISIN: DE000A0LD6E6) has been informed by the German Federal Financial Supervisory Authority (BaFin) that it is initiating an ad hoc financial report audit.
According to BaFin, the audit concerns the recognition of profits from contracts with custo......
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
News Preview
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.09.2025
ISIN: US6294442099
NRX Pharmaceuticals, Inc.
NRXP
LISTED
NASDAQ
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
News Preview
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx's patent-pending preservative-free ketamine product NEW YORK, NY / ACCESS Newswire / September 24, 2025 / NRx Pharmaceu...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
News Preview
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2 positive bre...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.09.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. To Present at Brookline Capital Markets
News Preview
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate CancerD-MNA and Teve...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ISIN: CH1335392721
Galderma Group AG
GALD
LISTED
XWSX
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
News Preview
Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from October 1-3, 2025. The company will also showcase its leadership in aesthetic education through a number of events including a symposium and medi...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
News Preview
Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (24-26 September)....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
News Preview
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
News Preview
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
News Preview
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnost...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Availability of the Q3 2025 Aide mémoire
News Preview
...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
